Singh S N, DiBianco R, Gottdiener J S, Ginsberg R, Fletcher R D
Am J Cardiol. 1984 Mar 1;53(6):745-50. doi: 10.1016/0002-9149(84)90397-7.
The antiarrhythmic efficacy of moracizin HCl (Ethmozine), a new oral phenothiazine derivative, was evaluated in 20 patients with chronic high-frequency ventricular arrhythmia confirmed by multiple ambulatory electrocardiographic recordings. Comparison with 72 +/- 24 hours (+/- standard deviation) of ambulatory recordings on moracizin treatment (average dose 295 +/- 58 mg 3 times daily or 9.8 +/- 1.0 mg/kg/day) was made. Maximal treadmill exercise provocation of arrhythmia and echocardiographic studies to detect effects on left ventricular function were also compared. The group had an average of 378 +/- 97 ventricular premature beats (VPBs) per hour while receiving placebo, with a mean VPB grade of 3.4 +/- 1.1 (modified Lown). When the patients received moracizin HCl, VPB frequency was reduced 53% (p less than 0.01), to a mean VPB grade of 2.2 +/- 1.4 (p less than 0.05). Seventy percent of the patients (14 of 20) showed a reduction in VPB frequency that exceeded the maximal expected variation; in 3 the frequency did not change and in 3 it increased with moracizin HCl. Resting electrocardiographic changes consisted of modest prolongations of PR interval (0.03 second) and QRS duration (0.02 second); however, QT prolongation was not observed. Heart rate and blood pressure at rest and peak exercise, exercise-related arrhythmia, exercise durations and echocardiographic measures of left ventricular function were unchanged by moracizin HCl compared with placebo. Side effects of moracizin++ HCl at these dosages were minimal (diarrhea in 1 patient, dizziness in 1 and diaphoresis in 1), although 2 patients tested at higher dosages had sustained ventricular tachycardia that may have been related to moracizin HCl.(ABSTRACT TRUNCATED AT 250 WORDS)
通过多次动态心电图记录确诊为慢性高频室性心律失常的20例患者，对新型口服吩噻嗪衍生物盐酸莫雷西嗪（乙吗噻嗪）的抗心律失常疗效进行了评估。将其与接受莫雷西嗪治疗（平均剂量295±58毫克，每日3次或9.8±1.0毫克/千克/天）72±24小时（±标准差）的动态记录进行了比较。还比较了最大量平板运动诱发心律失常情况以及检测对左心室功能影响的超声心动图研究。该组患者在接受安慰剂时，平均每小时有378±97次室性早搏（VPB），平均VPB分级为3.4±1.1（改良洛恩分级）。当患者接受盐酸莫雷西嗪治疗时，VPB频率降低了53%（p<0.01），平均VPB分级降至2.2±1.4（p<0.05）。70%的患者（20例中的14例）VPB频率降低超过最大预期变化；3例患者频率未变，3例患者使用盐酸莫雷西嗪后频率增加。静息心电图变化包括PR间期适度延长（0.03秒）和QRS时限适度延长（0.02秒）；然而，未观察到QT间期延长。与安慰剂相比，盐酸莫雷西嗪对静息和运动高峰时的心率、血压、运动相关心律失常、运动持续时间以及左心室功能的超声心动图测量值均无影响。这些剂量的盐酸莫雷西嗪副作用极小（1例患者出现腹泻，1例头晕，1例出汗），不过2例接受更高剂量测试的患者出现了持续性室性心动过速，可能与盐酸莫雷西嗪有关。（摘要截选至250词）
